Future research and clinical trials are crucial in determining the safety, efficacy, and suitability of NEK2 as a clinical therapy target or in combination with the standard of care for TNBC, offering new hope for patients facing limited treatment options in this aggressive breast cancer subtype. The gene discussed is NEK2; the disease is breast carcinoma.